Since the discovery of sickle cell disease (SCD) in 1910, enormous strides have been made
in the elucidation of the pathogenesis of its protean complications, which has inspired recent …

Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB,
which encodes haemoglobin subunit β. The incidence is estimated to be between 300,000 …

Sickle cell disease (SCD) is a genetic disorder, characterized by hemolytic anemia and vaso‐
occlusive crises (VOCs). Data on the global SCD impact on quality of life (QoL) from the …

Importance Individuals with sickle cell disease (SCD) have reduced life expectancy;
however, there are limited data available on lifetime income in patients with SCD. Objective …

Sickle cell disease (SCD) results in chronic hemolytic anemia, recurrent vascular occlusion,
insidious vital organ deterioration, early mortality, and diminished quality of life. Life …

Blood transfusion plays a prominent role in the management of patients with sickle cell
disease (SCD), but causes significant iron overload. As transfusions are used to treat the …

Etavopivat is an investigational, oral, small molecule activator of erythrocyte pyruvate kinase
(PKR) in development for the treatment of sickle cell disease (SCD) and other …

Rationale: Intraerythrocytic polymerization of Hb S promotes hemolysis and vasoocclusive
events in the microvasculature of patients with sickle cell disease (SCD). Although platelet …

In this retrospective, we review the two research topics that formed the basis of the
outstanding career of Dr. Paul S. Frenette. In the first part, we focus on sickle cell disease …

IntroductionA growing population of adults living with severe, chronic childhood-onset health
conditions has created a need for specialized health care delivered by providers who have …